

POLICY NAME	Tegsedi (inotersen)	POLICY #	2707P
--------------------	---------------------	-----------------	-------

Criteria

Coverage Criteria

- ☐ Diagnosis of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis
- ☐ Documentation that the patient has a pathogenic TTR gene mutation (e.g., V30M)
- ☐ Age 18 years or older
- ☐ Presence of clinical signs and symptoms of the disease (e.g., peripheral/autonomic nerve pain, motor disability, heart dysfunction, kidney dysfunction)
- ☐ One of the following:
 - Patient has a baseline polyneuropathy disability (PND) score IIIb
 - Patient has a baseline familial amyloidotic polyneuropathy (FAP) Stage 1 or 2
- ☐ Prescribed by or in consultation with a neurologist (nervous system doctor)

Exclusion Criteria – Any of the following prevents coverage

- ☐ Members also taking Onpattro (patisiran) or Amvuttra